GMV and the future of the Healthcare Industry, page-9

I noticed the increase in SP today of another biotech asx listed company. Im sure some GMV holders are invested in both. That one is in clinical trials looking to achieve FDA. No arguing that its a great product. However, its management Team does not have the credentials that GMV's does. No MOU's. Yet a similar market cap. At one stage, this other company had triple its market cap. Hence my belief, that when CFDA is achieved, and we begin reporting revenue, this will be at absolute minimum 3 x its current market cap. Each qtr that passes and revenue is shown, I think in 12mths we can be looking at $2.00 per share. All IMO, and no intention to ramp. Just my honest thoughts.